Novo Nordisk outlines new obesity and consumer-focused strategy, targets five multi-blockbusters by 2030

Novo Nordisk used its capital markets day to reassure investors by unveiling a plan to broaden its pipeline beyond diabetes and obesity. The company said it will aim to launch at least five multi-blockbuster products by 2030 and pursue a more consumer-oriented approach to new medicines.

CEO Mike Doustdar highlighted increased investment in disease areas outside its core GLP-1 franchise and promised a more active role in business development to reduce reliance on its landmark drugs.

Despite the ambitious roadmap, Novo shares fell about 5% during the presentation, reflecting investor demand for more concrete details on the upcoming products.

The strategy signals a shift toward treating medicines more like consumer goods, a move that could reshape Novo’s growth trajectory if successfully executed.